Ebola vaccine immunity under the microscope: how long does protection last?

NCT ID NCT05313139

Completed Knowledge-focused Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how long the Ebola vaccine (rVSV-ZEBOV) protects health workers in the Democratic Republic of the Congo. Researchers measured immune cells and antibodies in 133 vaccinated health workers to see if protection lasts beyond 1-2 years. The goal is to understand if booster shots are needed, especially after recent Ebola cases in previously vaccinated people.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rVSV-ZEBOV vaccine
What this could lead to: If successful, this could show how long the Ebola vaccine protects health workers and whether booster doses are needed.
What could go wrong: This is an observational study, not a treatment trial. It only measures immune responses and cannot prove the vaccine prevents future infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE RESPONSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE RESPONSE

Contacts and locations

Locations

Institut National de Recherche Biomédicale (INRB)

Goma, Democratic Republic of the Congo
Institut National de Recherche Biomédicale (INRB)

Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.